About Us

Mr. LIU Gexin

Chairman of the Board and non-Executive Director

Mr. LIU Gexin (刘革新), aged 75, was appointed as a Director and the chairman of the Board in November 2016 and March 2022, respectively. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Liu is the founder of Kelun Pharmaceutical and has served as the chairman of Kelun Pharmaceutical since its establishment. In addition, Mr. Liu currently has also held positions in a number of other company, including (i) the chairman of Sichuan Kelun Industry Group Co., Ltd. (四川科伦实业集团有限公司) since August 2000; (ii) the chairman of Yili Chuanning Biotechnology Co., Ltd. (伊犁川宁生物技术股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 301301) since June 2020; and (iii) a director of Chengdu Huaxi Clinical Research Co., Ltd. (成都华西临床研究中心有限公司) since July 2020.

Mr. Liu obtained his Master’s degree in cardiovascular pharmacology from Chongqing Medical College (重庆医学院) (currently known as Chongqing Medical University (重庆医科大学)) in China in June 1984. Mr. Liu also obtained his another Master’s degree in political economics from Southwest Normal University (西南师范大学) (currently known as Southwest University (西南大学)) in China in July 2003. Mr. Liu has received a series of awards and recognition, including (i) the National Model Worker (全国劳动模范) by The State Council, PRC (中华人民共和国国务院) in May 2005 (ii) the honorary title of “Outstanding Communist Party Member in Earthquake Relief” (抗震救灾优秀共产党员) by Sichuan Provincial Committee of the CPC and Chengdu Municipal Committee in 2008; (iii) an “Outstanding Builder of Socialism with Chinese Characteristics” (优秀中国特色社会主义建设者) by the United Front Work Department of the CPC Central Committee, the Ministry of Industry and Information Technology, the Ministry of Human Resources and Social Security, the State Administration for Industry and Commerce and the All-China Federation of Industry and Commerce in 2009; (iv) the “Medal in Commemoration of the 70th Anniversary of the People’s Republic of China” (庆祝中华人民共和国成立 70 周年纪念章) by the CPC Central Committee, the State Council and the Central Military Commission in 2019; (v) a member of the Party Committee of the Economic and Information Technology Industry Committee of the CPC Sichuan Province (中共四川省经济和信息化行业委员会) in April 2023; and (vi) a deputy director of the Standardisation Technical Committee of the China National Health Association (中国民族卫生协会标准化技术委员会) in November 2024. Mr. LIU Gexin is the father of Mr. LIU Sichuan, a non-Executive Director.

Dr. GE Junyou

General Manager, Executive Director

Dr. GE Junyou (葛均友), aged 54, was appointed as a Director in February 2022. He was redesignated as our Executive Director on February 15, 2023. Dr. Ge was appointed as the Chief Operation Officer of the Company in February 2021 and the general manager of the Company in March 2022. He is mainly responsible for overall corporate and business strategies of our Group and making key business and operational decisions of our Group. Dr. Ge has also served as a director and the Chief Executive Officer of KLUS PHARMA INC. in US since December 2021, an Executive director and manager of Sichuan Konas Pharmaceutical Co., Ltd. since November 2021, a director of the National Engineering Research Center of Targeted Biologics (生物靶向药物国家工程研究中心) since April 2022, Executive director and manager of Sichuan Kelun-Biotech Targeted Biologics Engineering Research Center Co., Ltd. (四川科伦博泰生物靶向药物工程研究中心有限公司) since March 2023, director and general manager of Kelun-Biotech Hong Kong Co., Limited since October 2023 and a director of Kelun Pharmaceutical since May 2024.

Dr. Ge has been engaged in the R&D, manufacturing and quality control, and corporate management of innovative drugs in the pharmaceutical industry both in China and abroad for over 30 years . The companies he has worked for include Shanghai Yan'an Pharmaceutical Factory (上海延安制药厂), Boehringer Ingelheim (勃林格殷格翰), Zhejiang Hisun (浙江海正药业 600267.SH) and Ratiopharm GmbH. Dr. Ge joined Kelun Pharmaceutical in June 2007 and served as a deputy general manager from July 2009 to February 2021, where he was mainly responsible for leading the quality management of Kelun Group. As a well-known cGMP expert in China, he participated in the revision, drafting, and review of the new Chinese GMP regulations, related guidelines and guiding principles, and co-authored five Professional Publications on GMP.

Dr. Ge obtained his bachelor’s degree in pharmacy from Shanghai Medical School (上海医科大学) (currently known as Shanghai Medical College Fudan University (复旦大学上海医学院)) in China. He obtained his Master’s degree in pharmaceutical engineering from East China University of Science and Technology (华东理工大学) and his doctoral degree in Biology and Medicine from Fudan University (复旦大学).

Dr. Ge is currently a standing committee member of the Sichuan Association for Science and Technology, a visiting professor at the Institute of Executive Development of NMPA, an expert reviewer for the Ministry of Science and Technology’s science and technology plan projects, a member of the Peer Review Expert Panel for the Hong Kong Innovation and Technology Commission, a member of the Third Council of China Center for International Economic Exchanges, a member of the Drug Testing Quality Management Committee of the Chinese Pharmaceutical Association, a member of Anti-cancer Drug Committee of the Chinese Pharmaceutical Association, Vice President of the China Quality Association for Pharmaceuticals, a Director of the Hong Kong Association of Overseas-Returned Scholars and a member of the Professional Committee on Drug Inspection and Compliance Research of China Society for Drug Regulation, etc.

Mr. LIU Sichuan

Non-Executive Director

Mr. LIU Sichuan (刘思川), aged 42, was appointed as a Director in November 2016. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Liu joined Kelun Pharmaceutical and served as the assistant of chairman in 2007. He has been serving as a director of Kelun Pharmaceutical since June 2009 and general manager of Kelun Pharmaceutical since September 2015. Currently he has also held positions in a number of other Company, including (i) a director of Sichuan Kelun Industry Group Co., Ltd. (四川科伦实业集团有限公司) since December 2015; (ii) a director of Yili Chuanning Biotechnology Co., Ltd. (伊犁川宁生物技术股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 301301), since June 2020; (iii) a manager and Executive director of Chengdu Kelun Jingchuan Technology Co., Ltd. (成都科伦晶川科技有限公司) since November 2021; and (iv) a director of China Resources Kelun (Sichuan) Medicine Limited (华润科伦医药 (四川) 有限公司) since September 2023.

Mr. Liu obtained his Master’s degree in international business from the University of Leeds in the United Kingdom in August 2007. Mr. Liu has received a series of awards and recognition, including (i) the “May Day Labour Medal of Hunan Province” (湖南省五一劳动奖章) awarded in 2014; (ii) the “Title of Outstanding Entrepreneur in Hunan Province” (“湖南省优秀企业家称号”) issued by Hunan Provincial Committee of the CPC and the People’s Government of Hunan Province (中共湖南省委、湖南省人民政府) on January 2018; (iii) the “National Advanced Individual in Fighting the COVID-19” (“全国抗击新冠肺炎疫情先进个人”) issued by CPC Central Committee, The State Council, PRC and the Military Commission of the CPC Central Committee (党中央、国务院、中央军委) in September 2020; (iv) the “4th Outstanding Non-Public Economic Contributor of Business in Socialism with Chinese Characteristics in Hunan Province” (第四届湖南省非公有制经济人士优秀中国特色社会主义事业建设者) awarded in 2021; and (v) the title of “the 4th Outstanding Contributor to the Development of Socialism with Chinese Characteristics in Sichuan Province” (第四届四川省优秀中国特色社会主义事业建设者) awarded in 2023. Mr. LIU Sichuan is the son of Mr. LIU Gexin the chairman of the Board and non-Executive Director.

Mr. LAI Degui

Non-Executive Director

Mr. LAI Degui (赖德贵), aged 55, was appointed as a Director in June 2024. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Lai has served as a deputy general manager and financial director of Kelun Pharmaceutical since October 2014 and the managing partner of Lishui Keyun Rentong Logistics Technology Limited Partnership (丽水市科运仁通物流科技合伙企业 (有限合伙)) since December 2020.

Mr. Lai received a diploma of accounting from Southwestern University of Finance and Economics (西南财经大学) through on-the-job learning in January 2013, and received a Master’s degree in business management from Tsinghua University (清华大学) in June 2023.

Mr. FENG Hao

Non-Executive Director

Mr. FENG Hao (冯昊), aged 46, was appointed as a Director in February 2021. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Feng has been serving as a deputy general manager and secretary of the board of directors of Kelun Pharmaceutical since April 2014 and the managing partner of Lishui Keyun Yaotong Logistics Technology Limited Partnership (丽水市科运耀通物流科技合伙企业 (有限合伙)) since December 2020. He also served as a non-Executive director of SSY Group Limited (石四药集团有限公司), a company listed on the Stock Exchange (stock code: 02005), from November 2017 to November 2023.

Prior to April 2014, Mr. Feng successively served as a tutor at the School of Economics at Huazhong University of Science and Technology (华中科技大学), an analyst at the Actuarial Division of Taiping Life Insurance Company Limited (太平人寿保险有限公司), an actuarial advisory consultant at Watson Wyatt Consultancy (Shanghai) Ltd. (上海华信惠悦 (咨询) 有限责任公司), a senior manager at the investment banking division of Ping An Securities Limited (平安证券有限责任公司) and a business director at the investment banking division of Sinolink Securities Co. Ltd (国金证券股份有限公司).

Mr. Feng obtained his Master’s degree in financial mathematics from Heriot-Watt University in the United Kingdom in November 2005. Mr. Feng has received a series of awards and recognition including the 2022, 2023 and 2024 5A Rating for Duty Performance of Board Secretary of Listed Companies (2022、2023 及 2024 年上市公司董事会秘书履职 5A 评级) by China Association for Public Companies (中国上市公司协会) on December 12, 2022, December 6, 2023 and December 17, 2024, respectively.

Ms. LIAO Yihong

Non-Executive Director

Ms. LIAO Yihong (廖益虹), aged 47, was a Supervisor from February 2022 to June 2025, and was redesignated as our non-Executive Director on June 20, 2025. She is mainly responsible for overseeing the management and strategic development of the Group.

Ms. Liao served as: (i) the chief director of audit of Kelun Pharmaceutical from December 2014 to April 2022, and was promoted as a deputy general manager of Kelun Pharmaceutical in April 2022; (ii) the supervisor of Chengdu Kelun Jingchuan Technology Co., Ltd. (成都科伦晶川科技有限公司) since November 2021; and (iii) the director and chairwoman of the board of Sichuan Kelun Doosan Biotechnology Co., Ltd. (四川科伦斗山生物技术有限公司) since February 2023.

From August 2002 to November 2014, Ms. Liao has successively served in Shenzhen branch of PricewaterhouseCoopers Zhongtian Certified Public Accountants (special general partnership) (普华永道中天会计师事务所 (特殊普通合伙)) and the Chengdu branch of KPMG Consulting (China) Co., Ltd. (毕马威企业咨询 (中国) 有限公司).

Ms. Liao obtained her bachelor’s degree in accounting from Guangdong University of Foreign Studies (广东外语外贸大学) in China in June 2002. She obtained her Master’s degree in accounting from Tsinghua University (清华大学) through on-the-job learning in China in June 2021.

Mr. ZENG Xuebo

Non-Executive Director

Mr. ZENG Xuebo (曾学波), aged 41, was appointed as a Director in July 2022. He was redesignated as our non-Executive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Formerly he served as a manager and was then promoted as a director of Shenzhen Zhongyi Yingtai Venture Capital Co., Ltd. (深圳中逸盈泰创业投资有限公司). From June 2015 to July 2016, he served as a deputy director of Shenzhen Investment Holdings Donghai Investment Co., Ltd. (深圳投控东海投资有限公司). From August 2016 to October 2020, he served as a director and was then promoted as a vice president of Aiqi Venture Capital Management (Shenzhen) Co., Ltd. (爱奇创业投资管理 (深圳) 有限公司). He has successively served as a vice president and managing director of Zhuhai Hexie Zhuorui Private Equity Fund Management Co., Ltd. (珠海和谐卓睿私募基金管理有限公司) (formerly “Hexie Zhuorui (Zhuhai) Investment Management Co., Ltd. (和谐卓睿 (珠海) 投资管理有限公司)”) from November 2020 to October 2025. He served as a managing director of Hainan Harmony Hengxin Private Equity Investment Fund Management Co., Ltd. (海南和谐恒兴私募股权投资基金管理有限公司) since October 2025. Additionally, from January 2022 to September 2023, he served as a director of Hangzhou Sciwind Biosciences Co., Ltd. (杭州先为达生物科技有限公司). From September 2022 to September 2025, he served as a director of Shanghai Model Organisms Center, Inc. (上海南方模式生物科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688265).

Currently he also holds positions in various companies, including (i) a director of Shandong Bestcomm Pharmaceutical Company Limited (山东百诺医药股份有限公司), since January 2018; (ii) a director of Chiral Quest (Suzhou) Co., Ltd. (凯瑞斯德生化 (苏州) 有限公司), since December 2022; (iii) a director of Jiangxi Longlife Bio-pharmaceutical Co., Ltd. (江西隆莱生物制药有限公司), since February 2023; (iv) a director of Suzhou Pengxu Pharmatech Co., Ltd. (苏州鹏旭医药科技有限公司), since February 2023; (v) an independent director of CASI Pharmaceuticals, Inc., a company listed on NASDAQ (stock code: CASI), since March 2023; (vi) a director of Zhejiang Ablaze Health Technology Co., Ltd (浙江艾比奥健康科技有限公司), since March 2023; and (vii) a director of ZenCore (Cayman) Limited, since November 2023; (viii) a non-Executive director of Chengdu Pukangweixin Biotechnology Technology Co., Ltd. (成都普康唯新生物科技有限公司), since May 2024; (ix) a non-Executive Director of Sunshine Lake Pharma Co., Ltd. (广东东阳光药业股份有限公司) (a company listed on the Stock Exchange (stock code: 6887) since August 7, 2025), since December 2024; (x) a director of Chengdu Maxvax Biotechnology Co., Ltd. (成都迈科康生物科技有限公司) since October 2025; and (xi) a director of Hainan Harmony Hengxin Private Equity Investment Fund Management Co., Ltd. (海南和谐恒兴私募股权投资基金管理有限公司) since October 2025.

Mr. Zeng obtained his bachelor's degree in pharmacy from Qinghai Minzu University in China in July 2009.

Dr. ZHENG Qiang

Independent Non-Executive Director

Dr. ZHENG Qiang (郑强), aged 65, was appointed as an independent non-Executive Director on February 15, 2023 with effect from July 2023. He is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Zheng joined the Peking University (北京大学) in 2005, and he has been serving as a professor and doctoral supervisor in industrial engineering and management in Peking University (北京大学) until his retirement on January 27, 2024.

Dr. Zheng obtained his bachelor’s degree in physics from Peking University (北京大学) in China in July 1983. Dr. Zheng obtained his Master’s degree in physics from Graduate School of Chinese Academy of Sciences (中国科学院研究生院) (currently known as University of Chinese Academy of Sciences (中国科学院大学) in China) in August 1986. He also obtained his doctoral degree in physics from Temple University in the United States in June 1989.

Dr. TU Wenwei

Independent Non-Executive Director

Dr. TU Wenwei (涂文伟), aged 60, was appointed as an independent non-Executive Director on February 15, 2023 with effect from July 2023. He is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Tu successively served as a lecturer and attending doctor at the department of paediatrics of Children’s Hospital, Chongqing Medical University (重庆医科大学附属儿童医院) and a postdoctoral researcher fellow in the department of pediatrics at the Stanford University School of Medicine in the United States before 2006. Dr. Tu has served as a professor in the department of paediatrics & adolescent medicine, Li Ka Shing Faculty of Medicine at The University of Hong Kong (the “HKU”) since June 2015. Dr. Tu also held various positions, such as the assistant dean of the Li Ka Shing Faculty of Medicine since October 2011 and an associate professor since June 2009 at the department of paediatrics & adolescent medicine since joining HKU in 2006.

Dr. Tu obtained his bachelor’s and Master’s degrees in medicine sciences from Chongqing Medical University (重庆医科大学) in the PRC in July 1989 and December 1992, respectively. He obtained his doctoral degree in philosophy from HKU in December 1999. Dr. Tu has received a series of awards including several Prize of Science and Technology Progress (科技进步奖). He was also recognized as a Changjiang scholar chair professor in pediatrics (长江学者讲座教授 (儿科)) by Ministry of Education of PRC (中华人民共和国教育部) in April 2016.

Dr. JIN Jinping

Independent Non-Executive Director

Dr. JIN Jinping (金锦萍), aged 54, was appointed as an independent non-Executive Director on February 15, 2023 with effect from July 2023. She is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Jin serves as an associate professor in the Law School, Peking University (北京大学). She has been serving as an independent non-Executive Director of Horizon Construction Development Limited (宏信建设发展有限公司), a company listed on the Stock Exchange (stock code: 9930), since May 2021. Ms. Jin served as an independent director of China Automotive Engineering Research Institute Co., Ltd. (中国汽车工程研究院股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 601965) from January 2020 to December 2025, and an independent director of Beijing Oriental Jicheng Co., Ltd. (北京东方中科集成科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002819) from July 2018 to June 2024.

Dr. Jin obtained a bachelor’s degree in economic law from Peking University (北京大学) in the PRC in July 1995, a Master’s degree in civil and commercial law from Peking University in July 2001, and a doctorate degree in civil and commercial law from Peking University in June 2004. Dr. Jin obtained a lawyer qualification granted by the Ministry of Justice of the PRC in June 1997 and higher education teacher qualification granted by the Beijing Municipal Education Commission in December 2008. Dr. Jin has served as a director of the China Red Cross Foundation since September 2016.

Dr. LI Yuedong

Independent Non-Executive Director

Dr. LI Yuedong (李越冬), aged 49, was appointed as an independent non-Executive Director on February 15, 2023 with effect from July 2023. She is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Li joined the Southwestern University of Finance and Economics (西南财经大学) in 2004 and she has been serving as a doctoral supervisor in Auditing at Southwestern University of Finance and Economics (西南财经大学) since January 2022. She has been serving as (i) an independent director of Chengdu Sino Microelectronics Technology Co., Ltd. (成都华微电子科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688709), since September 2021; (ii) an independent director of Ya'an Baitu High Tech Materials Co., Ltd. (雅安百图高新材料股份有限公司) since September 2022; (iii) an independent director of Chengdu Shengbang Seals Co., Ltd. (成都盛帮密封件股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 301233), since November 2022; and (iv) an independent non-Executive director of Honghua Group Limited (宏华集团有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 196) since June 2024. In addition, Dr. Li also served as (i) an independent director of Chengdu Hi-Tech Development Co., Ltd. (成都高新发展股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000628) from June 2015 to June 2022; (ii) an independent director of Sichuan Fengsheng Paper Technology Co., Ltd. (四川凤生纸业科技股份有限公司) from December 2019 to December 2022; (iii) an independent director of Sichuan Neautus Traditional Chinese Medicine Co., Ltd. (四川新荷花中药饮片股份有限公司) from January 2020 to February 2023; and (iv) an independent director of Chengdu Leejun Industrial Co., Ltd. (成都利君实业股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002651) from July 2021 to May 2024; (v) an independent director of Chengdu Zhimingda Electronics Co., Ltd. (成都智明达电子股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688636), from November 2022 to November 2025; and (vi) an external supervisor of Sichuan Beichuan Rural Commercial Bank Co., Ltd. (四川北川农村商业银行股份有限公司) from December 2023 to November 2025.

Dr. Li obtained her bachelor’s degree in economics from Chongqing Business College (重庆商学院) (currently known as Chongqing Technology and Business University (重庆工商大学)) in China in July 2000. Dr. Li obtained her Master’s degree in accountancy from Georgia State University in the United States in May 2004. She also obtained her doctoral degree in business administration from Southwestern University of Finance and Economics (西南财经大学) in China in January 2011, completed the joint post-doctoral program between the National Audit Office of China (中国审计署) and Peking University in 2015 and served as a research fellow of the Institute of Chartered Accountants in England and Wales (ICAEW) in 2021. Dr. Li was appointed as an external doctoral supervisor for the DBA at Lyon Business School, France, in July 2022, and was certified as a public accountant by the Guam Board of Accountancy, the United States, in August 2015 and was certified as a public accountant by Certified Practising Accountant Australia in August 2025. She also participated numerous times in United Nations audit projects of the National Audit Office of China and completed the audit training course at the United Nations in June 2020. Dr. Li has received a series of awards and recognition. She was recognized as an internationalized high-end accounting talent (国际化高端会计人才) by the Ministry of Finance of the PRC (中国财政部) in December 2021.